Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort study.
The benefit of adding programmed cell death protein 1 (PD-1) blockade to hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib for unresectable hepatocellular carcinoma remains uncertain. This single-center retrospective cohort study included 373 patients. After propensity score matching, 107 patients treated w...